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Abstract Epidemiological studies strongly suggest associations
between chronic exposure to endogenous oestrogens and the
development of breast and gynaecological tumours. Two mech-
anisms by which 17L-oestradiol (E2) may enhance tumorigenesis
are: (i) enhancement of cell proliferation and (ii) the production
of reactive, genotoxic metabolites. Here we suggest an addi-
tional mechanism, inhibition of DNA repair. The removal of
UV-induced thymine dimers from human keratinocytes, re£ec-
tive of nucleotide excision repair, was signi¢cantly attenuated
by treatment of cells with E2. In contrast, treatment with 17K-
oestradiol had no e¡ect. Mechanisms are proposed for this ef-
fect of E2, which may contribute to its carcinogenic potential.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Epidemiological studies have shown that prolonged expo-
sure to oestrogens, particularly 17L-oestradiol (E2), is one of
the primary risk factors for the development of tumours, par-
ticularly those of breast and gynaecological tissues [1]. The
risk of developing such tumours is related to the length of
exposure to endogenous oestrogens, with factors such as early
menarche, late ¢rst pregnancy, low parity and late menopause
all increasing risk [1^3].
Mechanistically, E2 may exert its carcinogenic actions by at
least two principal, and not necessarily mutually exclusive,
routes: ¢rstly, through stimulating cell proliferation and sec-
ondly via the genotoxicity of metabolites [4]. The growth pro-
moting action of E2 almost certainly involves positive modu-
lation of cell cycle proteins, at the levels of gene expression
and protein function, either through initial interaction with
oestrogen receptors (ERs) or possibly via non-genomic mech-
anisms [5,6]. Hydroxylation of E2, catalysed by several en-
zyme activities, particularly cytochrome P450s, can produce
the catecholoestrogens, 2- or 4-hydroxyoestradiol [7]. Subse-
quent redox metabolism of these catechols may ultimately
form quinones and reactive oxygen species, which can modify
DNA, producing potentially mutagenic lesions, or induce
chromosomal aberrations [8,9]. In this report we postulate
that E2 may have an additional property in relation to carci-
nogenesis, an ability to down-regulate DNA repair. Although
not an unknown phenomenon, there are very few reports in
the literature relating to an ability of endogenous steroidal sex
hormones to modulate DNA repair, certainly an e¡ect of
these compounds on nucleotide excision repair (NER) specif-
ically has not been reported [10^12]. In this report we show
that treatment of a human keratinocyte cell line with E2 re-
sults in an attenuation of the removal of cyclobutane thymine
dimers (TGfT), as measured by immunoassay. The repair of
TGfT, induced by UV irradiation, occurs exclusively by NER
in human cells and therefore provides a convenient method to
examine this repair pathway.
2. Materials and methods
2.1. Materials
E2 and 17K-oestradiol were obtained from Sigma Chemical Co.
(Poole, UK). Spontaneously immortalised human keratinocytes, Ha-
CaT cells, were a kind gift from Professor N.E. Fusenig (Deutsches
Krebsforschungszentrum, Heidelberg, Germany [13]) and cell culture
medium (RPMI 1640) was from Gibco BRL/Life Technologies (Pais-
ley, UK). Foetal bovine serum was stripped of endogenous oestrogens
using charcoal as described by Thibodeau et al. [14]. Anti-TGfT anti-
body was produced and characterised ‘in house’ as described by Ah-
mad et al. [15]. Unless stated otherwise all other materials and chem-
icals were from Fisher Scienti¢c (Loughborough, UK) or Sigma
Chemical Co.
2.2. Exposure of cells to oestradiols and induction of thymine dimers
HaCaT cells were cultured in 6 well plates, at a density of 1U104
cells/cm2 in phenol red-free RPMI 1640 containing 1% charcoal-
stripped foetal bovine serum and 2 mM glutamine, overnight at
37‡C, 5% CO2. This medium was then replaced with fresh medium
containing various concentrations of oestradiol. After 24 h, the me-
dium was removed and the cells washed with phosphate bu¡ered sa-
line and placed in Hanks’ bu¡ered saline solution containing magne-
sium and calcium salts. To induce TGfT the cells were then irradiated
in a light box with a UV-B source (95% UV-B, 5% UV-A) for a total
of 240 mJ/cm2 (UV-B), after which time the Hanks’ bu¡ered saline
solution was removed and the cells were returned to 37‡C/5% CO2 in
RPMI medium containing 1% charcoal-stripped foetal bovine serum
and 2 mM glutamine for de¢ned times.
2.3. Cell viability (MTT assay)
Post UV irradiation, cell viability was measured using the MTT
assay, as previously described [16]. The assay is based on the ability
of dehydrogenases in viable cells to cleave the tetrazolium ring of
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide to yield
purple formazan crystals which are insoluble in aqueous solutions.
The crystals are subsequently solubilised in dimethyl sulphoxide and
the resultant solution is measured spectrophotometrically at 570 nm.
An increase or decrease in cell number (and presumably dehydroge-
nase activity) corresponds to a concomitant change in the amount of
formazan crystals formed, giving an indication of the cytotoxicity of
the UV-B treatment. In this study, MTT was added to the cells for 2 h
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at a ¢nal concentration of 0.5 mg/ml. After the MTT containing
medium was removed, the cells were washed with phosphate bu¡ered
saline (PBS) and the formazan product dissolved and measured.
2.4. Measurement of thymine dimers in HaCaT genomic DNA
At speci¢ed time points, both cells and cell culture medium super-
natants were collected. The genomic DNA was extracted from the
cells using a Genomic DNA Wizard Preparation kit (Promega UK,
Southampton, UK). The protein content of each sample was calcu-
lated from the protein fraction of the cells using a BCA protein assay
(Perbio Science UK, Tattenhall, UK). Genomic DNA extracted from
the samples was analysed for TGfT content using a direct ELISA
protocol based upon that described by Cooke et al. [17]. Brie£y,
extracted DNA was rendered single stranded by boiling and rapid
cooling on ice, then bound to Nunc-Immuno Maxisorp 96 well plates
(Life Technologies) coated with poly-L-lysine. Following blocking of
the free binding sites, the IgG fraction of a polyclonal rabbit anti-
serum which detects TGfT [15] was added at a dilution of 1/1000.
Detection was via a peroxidase labelled swine anti-rabbit secondary
antibody (Dako, High Wycombe, UK) in conjunction with an ortho-
phenylenediamine substrate solution. The reaction was stopped using
2 M H2SO4 and the resultant absorbance was read on a plate reader
(Anthos-Labtec 2001, Anthos-Labtec Instruments, East Sussex, UK)
at 492 nm. The readings were corrected for background absorbance.
2.5. Measurement of thymine dimers in HaCaT cell culture medium
Quanti¢cation of excised TGfT in the supernatants of irradiated cells
was carried out using a competitive ELISA based on that used pre-
viously for the urinary analysis of TGfT [15]. Brie£y, a solution of
single stranded, UV-C irradiated calf thymus DNA (solid phase anti-
gen) was bound to poly-L-lysine coated 96 well plates. Following
blocking of the free binding sites with 4% w/v milk power in PBS,
an aliquot of cell culture supernatant was added to the plates, along
with the IgG fraction of a polyclonal rabbit antiserum which detects
TGfT, as above, at a ¢nal dilution of 1:1000. Primary antibody bind-
ing was quanti¢ed as described in Section 2.4.
2.6. Immunocytochemical detection of ERK in HaCaT cells
HaCaT cells were grown to con£uence in chamber slides with phe-
nol red-free RPMI 1640, plus 2 mM glutamine and 10% v/v stripped
serum at 37‡C, 5% CO2. After reaching con£uence, medium was
removed and replaced with the above medium plus 1% stripped serum
overnight. Fresh medium containing 0 (ethanol vehicle only), 200 pM
or 5 nM E2 in ethanol was then added and the cells left for 24 h. After
24 h the culture medium was removed and the cell layer gently washed
with PBS, ¢xed with ethanol (4^5 min) and washed with PBS. Follow-
ing blocking with serum (2% v/v) for 1 h at 37‡C, then washing with
PBS, a 1/100 dilution in serum of mouse monoclonal anti-human ERK
primary antibody (Dako Cytomation, Ely, UK) was added and incu-
bated for 2 h at 37‡C. Following washing with PBS, a 1/40 dilution of
FITC conjugated rabbit anti-mouse immunoglobulin secondary anti-
body (Dako Cytomation) was added and incubated for 0.5 h, then the
cells were washed with PBS. The ¢xed and stained cells were then
viewed using £uorescence microscopy.
Fig. 1. The e¡ects of E2 and 17K-oestradiol on the viability of HaCaT cells following UV-B irradiation. The results are presented as
meanSS.D. (n=3); signi¢cantly di¡erent from 0 h, *P9 0.05.
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2.7. Statistical analysis
All results were corrected for protein content (mg/ml) and the re-
sults are presented as a ratio of non-irradiated samples. In each case
the results presented represent the mean of three experiments, with
standard deviations presented as a indication of the reproducibility of
the assay. Statistical analysis was carried out on each result using
Student’s t-test provided as part of GraphPad Prism software
(v2.01; GraphPad Software, San Diego, CA, USA).
3. Results
A signi¢cant decrease in viability, as measured by the MTT
assay, post UV irradiation, was not detected until 24 h for
all treatments compared to the initial time point (Fig. 1;
P6 0.05). Exposure to E2 or 17K-oestradiol did not signi¢-
cantly a¡ect post-irradiation viability, irrespective of concen-
tration. The reduction of MTT is predominantly dependent
on the activity of cytosolic, pyridine nucleotide dependent
dehydrogenases, while some previous observations in the lit-
erature have indicated that the MTT assay can be used to
report on cell proliferation, with a direct relationship between
MTT dye reduction and cell number, thus the assay can be
used as a measure of cell viability [18].
The measurement of genomic levels of TGfT showed an in-
duction of lesions immediately post UV-B exposure and a
slow loss of lesions over time, re£ective of DNA repair
(Fig. 2). As shown, the data are all corrected for protein
content to account for cell number and also levels of lesion
are shown relative to a control not exposed to UV radiation
or E2. On this basis, immediately following UV irradiation,
levels of TGfT at least doubled in irradiated cells irrespective of
E2 treatment (Fig. 2). By 24 h, the level of TGfT returned
almost to control, unirradiated levels. Since TGfT are removed
by NER, this removal re£ects the activity of this pathway.
Although some loss of cell viability may have an impact on
the data at the 24 h time point, since genomic DNA is ex-
tracted from the adherent cell population, and non-viable cells
will detach, the 24 h data should represent lesion levels in
viable cells. Pre-treatment of cells with both 200 pM (physio-
Fig. 2. The e¡ects of exposure of HaCaT cells to E2 and 17K-oestradiol on thymine dimer content in genomic DNA following UV-B irradia-
tion. The results are expressed as a fold increase in thymine dimer content over non-irradiated samples and the results are normalised for pro-
tein content. Results are presented as meanSS.D. (n=3 experiments); signi¢cantly di¡erent compared to control, *P9 0.05, **P9 0.02,
***P9 0.01.
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logical level) and 5 nM (supra-physiological level) E2 induced
an appreciable delay in the removal of TGfT, which became
signi¢cantly di¡erent at 2 h. In contrast, 17K-oestradiol, a
physiologically inactive isomer of E2, did not delay removal
of TGfT and removal paralleled that of the non-E2 treated cells
(Fig. 2). The removal of TGfT from genomic DNA was re-
£ected by supernatant levels of excreted repair products, TGfT,
analysed by competitive ELISA (Fig. 3). In this case, E2 pre-
treatment suppressed excretion of TGfT compared to control
cells and as with genomic DNA TGfT levels, 17K-oestradiol
pre-treatment paralleled the excretion pattern of untreated
cells. A signi¢cant di¡erence between E2 pre-treated and un-
treated cells only became signi¢cant at 4 h and later time
points; at 24 h, loss of cell viability may begin to impact on
the supernatant levels of lesions. In all of these experiments,
oestrogen exposure was performed prior to irradiating the
cells, and cells were not incubated in a medium containing
supplemental oestrogens after irradiation.
A qualitative immunocytochemical analysis revealed that
HaCaT cells grown under the experimental conditions ex-
pressed ERK. A suitable quantitative analysis of expression
was not feasible, in part because culturing HaCaT cells with
E2 led to notable detachment of the cells from the chamber
slides; modulation of cellular adherence by E2 treatment has
been noted in the literature [19]. However, a purely visual
examination suggested that those cells that had been exposed
to exogenous E2 displayed more intense £uorescence.
4. Discussion
Collectively, the data strongly suggest that E2 attenuates the
repair of TGfT in HaCaT cells and, by implication, attenuates
the activity of NER. The inhibition of DNA repair by endog-
enous steroidal sex hormones, including E2 and progesterone,
was reported in the early 1970s, but since then few reports of
this phenomenon have been noted [10,11]. However, these
early studies used hormone concentrations that were well
above those found physiologically, unlike in the present study
where we used concentrations within (200 pM) or relatively
close to (5 nM) physiological levels in healthy females. A few
other studies, in vivo or using synthetic oestrogen, provide
further, albeit limited, evidence for the potential of female
sex steroids to modulate DNA repair, but do not speci¢cally
refer to NER [12,20].
Fig. 3. The e¡ects of E2 and 17K-oestradiol on the release of thymine dimers into the medium of HaCaT cells exposed to UV-B irradiation.
Experimental details are described in the legend to Fig. 2. Results are presented as meanSS.D. (n=3 experiments); signi¢cantly di¡erent com-
pared to control, *P9 0.05, **P9 0.02, ***P9 0.01.
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Collectively, several observations from the literature imply
that E2 has the potential to attenuate NER and hence support
our ¢ndings in this study. Functional inactivation of p53
through relocalisation to the cytoplasm has been observed
in E2 treated MCF-7 cells [21]. This would seem to be signi¢-
cant as p53 is important for e⁄cient global genome repair of
TGfT by NER, through modulation of activity/expression of
repair proteins or induction of cell cycle arrest [22,23]. Evi-
dently, if p53 function is impaired in some way, cell cycle
checkpoint function may also be impaired. By acting as a
proliferating agent, E2 may drive cell proliferation to diminish
cell cycle checkpoint function and accompanying DNA repair
activities, which has been postulated to contribute to the in-
duction of genetic errors in the genesis of breast and endome-
trial cancers [1]. Furthermore, E2 can up-regulate mdm2 ex-
pression; MDM2 binds to activated p53 and targets it for
transport to the cytoplasm and degradation by the protea-
some [24]. The targeted degradation of repair proteins by
the proteasome is an additional mechanism by which E2
may modulate NER, apart from any uncharacterised e¡ect
it may have on NER repair protein expression. Recent data
suggest that E2 increases the expression of components of the
proteasome complex [25] ; the ubiquitin^proteasome pathway
for protein degradation is a route whereby NER may be
regulated [26]. Elevated expression of the anti-apoptotic pro-
tein Bcl-2 is also reported to increase proteasome activity [27].
At a concentration of 1 nM, E2 induces expression of Bcl-2 in
the ER positive cell line MCF-7 [28]. Cells over-expressing
Bcl-2 show an attenuation of NER and repair of oxidative
DNA lesions such as thymine glycol and 8-oxo-2P-deoxygua-
nosine [29,30]. This suggests a further connection between E2
exposure and the down-regulation of DNA repair, although
the mechanistic links are presently unclear. It is also possible
that the anti-apoptotic action of Bcl-2 may be important in
promoting the survival of cells harbouring unrepaired DNA,
thus providing an additional carcinogenic mode of action for
E2.
While the above discussion is speculative, what was evident
mechanistically from the present study was that 17K-oestra-
diol apparently had no e¡ect on the repair of TGfT, implying
that E2 may attenuate NER through interaction with ER,
either classical nuclear receptors or ectopically expressed ER
[31,32]. Immunocytochemistry revealed that HaCaT cells can
and do express ERK, consistent with observations of the ex-
pression of functional ER in dermal keratinocytes suggested
by several studies [33^35]. Whether this DNA repair modulat-
ing e¡ect of E2 is limited to a few cell types, perhaps only
those harbouring functional ER, remains to be examined.
We suggest that an inhibitory action of E2 on NER and
perhaps other DNA repair pathways may have pathological
signi¢cance and implies an additional mechanism whereby
this compound may in£uence carcinogenesis in responsive tis-
sues. There are several reports of the positive in£uence of
impaired DNA repair on the process of carcinogenesis to
imply that this concept is feasible [36,37] and although the
data are sparse, a relationship between gender (possibly re-
lated to hormonal in£uence), carcinogenesis and the repair of
UV induced DNA damage has been reported [38]. However,
there is no doubt that a considerable amount of work remains
to be done with regard to exactly how E2 may modulate NER
and whether it has similar e¡ects on other DNA repair path-
ways. Furthermore, the e¡ects of related steroidal hormones
may also warrant investigation and hopefully this report will
provide fresh impetus for such work.
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